{"title":"Industry updates in the field of therapeutic delivery in June 2024.","authors":"Mengistie Diress, Armin Mooranian, Hani Al-Salami","doi":"10.1080/20415990.2024.2408214","DOIUrl":"https://doi.org/10.1080/20415990.2024.2408214","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy.","authors":"Nalla Usha Kumari, Ekta Pardhi, Padakanti Sandeep Chary, Neelesh Kumar Mehra","doi":"10.4155/tde-2023-0092","DOIUrl":"10.4155/tde-2023-0092","url":null,"abstract":"<p><p>Breast cancer (BC) is a heterogeneous disease with various morphological features, clinicopathological conditions and responses to different therapeutic options, which is responsible for high mortality and morbidity in women. The heterogeneity of BC necessitates new strategies for diagnosis and treatment, which is possible only by cautious harmonization of the advanced nanomaterials. Recent developments in vesicular nanocarrier therapy indicate a paradigm shift in breast cancer treatment by providing an integrated approach to address current issues. This review provides a detailed classification of various nanovesicles in the treatment of BC with a special emphasis on recent advances, challenges in translating nanomaterials and future potentials.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"279-303"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139906512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapeutic deliveryPub Date : 2024-04-01Epub Date: 2024-02-29DOI: 10.4155/tde-2023-0101
Rachana Pockle, Rajashree Masareddy, Vijay Bambulkar, Rishabh Desai, Sai Kiran
{"title":"Exploring magnesium myristate for its dual functionality as a binder and lubricant in the formulation of tablet.","authors":"Rachana Pockle, Rajashree Masareddy, Vijay Bambulkar, Rishabh Desai, Sai Kiran","doi":"10.4155/tde-2023-0101","DOIUrl":"10.4155/tde-2023-0101","url":null,"abstract":"<p><p><b>Purpose:</b> To explore 'magnesium myristate' for its dual functionality as a lubricant and binder in the formulation of tablets. <b>Methods:</b> Using (DoE), tablet formulations using magnesium myristate and conventional excipients (magnesium stearate and PVP K30) were developed by wet granulation technique. The prepared granules and formulated tablets were evaluated for pre- and post-compression parameters, respectively. <b>Results:</b> Magnesium myristate exhibited excellent flow properties. The optimized formulations containing magnesium myristate exhibited increased hardness and <i>in vitro</i> drug release in comparison to conventional excipients. <i>f</i><sub>2</sub> similarity index for <i>in vitro</i> drug release showed no significant variations with optimized formulations and with the marketed formulations. <b>Conclusion:</b> Magnesium myristate shows a promising replacement for conventional excipients as both a lubricant and binder in tablet formulation.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"253-266"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapeutic deliveryPub Date : 2024-04-01Epub Date: 2024-03-07DOI: 10.4155/tde-2023-0140
Ahmed Munef, Zainab Lafi, Naeem Shalan
{"title":"Investigating anti-cancer activity of dual-loaded liposomes with thymoquinone and vitamin C.","authors":"Ahmed Munef, Zainab Lafi, Naeem Shalan","doi":"10.4155/tde-2023-0140","DOIUrl":"10.4155/tde-2023-0140","url":null,"abstract":"<p><p><b>Background:</b> Thymoquinone (TQ) and vitamin C (Vit C) have demonstrated individual anticancer effects in various studies. TQ exhibits inhibitory properties against tumor growth, induces apoptosis, while Vit C protects against DNA damage and oxidative stress. <b>Aim:</b> Formulation of TQ and Vit C combination into liposomes using two methods and investigate the synergistic anticancer. <b>Method:</b> Liposomal preparations were characterized, and the purity of drug components was confirmed using encapsulation efficiency (EE %). <b>Results:</b> <i>In vitro</i> cell viability studies demonstrated the inhibitory effect of TQ and Vit C against colorectal (HT29, 5.5 ± 0.9 μM) and lung cancer (A549, 6.25 ± 0.9 μM) cell lines with combination index <1. <b>Conclusion:</b> The formulation of TQ and Vit C displayed synergistic anticancer activity.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"267-278"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapeutic deliveryPub Date : 2024-04-01Epub Date: 2024-03-12DOI: 10.4155/tde-2023-0099
Susbin Raj Wagle, Bozica Kovacevic, Corina Mihaela Ionescu, Thomas Foster, Melissa Jones, Momir Mikov, Andrew Wise, Armin Mooranian, Hani Al-Salami
{"title":"Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an <i>in vitro</i> study.","authors":"Susbin Raj Wagle, Bozica Kovacevic, Corina Mihaela Ionescu, Thomas Foster, Melissa Jones, Momir Mikov, Andrew Wise, Armin Mooranian, Hani Al-Salami","doi":"10.4155/tde-2023-0099","DOIUrl":"10.4155/tde-2023-0099","url":null,"abstract":"<p><p><b>Aim:</b> Excessive free radicals contribute to oxidative stress and mitochondrial dysfunction in sensorineural hearing loss (SNHL). The antioxidant probucol holds promise, but its limited bioavailability and inner ear barriers hinder effective SNHL treatment. <b>Methodology:</b> We addressed this by developing probucol-loaded nanoparticles with polymers and lithocholic acid and tested them on House Ear Institute-Organ of Corti cells. <b>Results:</b> Probucol-based nanoparticles effectively reduced oxidative stress-induced apoptosis, enhanced cellular viability, improved probucol uptake and promoted mitochondrial function. Additionally, they demonstrated the capacity to reduce reactive oxygen species through the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway. <b>Conclusion:</b> This innovative nanoparticle system holds the potential to prevent oxidative stress-related hearing impairment, providing an effective solution for SNHL.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"237-252"},"PeriodicalIF":4.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synthesis and evaluation of amylose-mefenamic acid conjugates as colon-targeting prodrugs.","authors":"Shraddha Chugh, Mousmee Sharma, Harish Mudila, Parteek Prasher","doi":"10.4155/tde-2023-0106","DOIUrl":"10.4155/tde-2023-0106","url":null,"abstract":"<p><p><b>Aim:</b> Amide-linked amylose-based prodrugs were developed for colon-targeted release of mefenamic acid. <b>Materials & methods:</b> Activation of prodrug was studied spectrophotometrically, enzyme-linked immunosorbent assay appraised cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibition at different concentrations of the prodrug, the behavior of prodrug under physiological conditions was monitored by scanning electron microscopy. <b>Results:</b> Prodrug was poorly activated in the enzyme-free simulated gastric media and simulated intestinal media (SIM) but preincubation in pancreatin followed by treatment in aminopeptidase containing SIM led to a significant activation of prodrug. <b>Conclusion:</b> Amide-linked amylose-mefenamic acid conjugates showed a slow release in simulated gastric media and a controlled release in SIM with pancreatin playing an important role in drug release.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hasan Al-Nasrawi, Naeem Shalan, Bassam M Abualsoud, Hamdi Nsairat
{"title":"Preparation, characterization and <i>in vitro</i> evaluation of 5-fluorouracil loaded into chitosan-acacia gum nanoparticles.","authors":"Hasan Al-Nasrawi, Naeem Shalan, Bassam M Abualsoud, Hamdi Nsairat","doi":"10.4155/tde-2023-0136","DOIUrl":"10.4155/tde-2023-0136","url":null,"abstract":"<p><p><b>Aim:</b> In this study, we prepared, characterized and <i>in vitro</i> evaluated a 5-fluorouracil (5-FU)-loaded chitosan-acacia gum nanoparticles. <b>Methods:</b> Nanoparticles were characterized for their size, charge, morphology and encapsulation efficiency (EE%) followed by cellular investigations against HT-29 colon cancer cell line. <b>Results:</b> The nanoparticles exhibited a spherical morphological size with 94.42% EE%. Free 5-FU showed a fast and fully cumulative release after 6 h while 5-FU loaded into CS-AG NPs showed good entrapment and slow, prolonged 5-FU release even after 24 h. Enhanced IC<sub>50</sub> for the 5-FU loaded NPs compared with free 5-FU against HT-29 colon cancer cell line was reported with high selectivity compared with normal fibroblast cells. <b>Conclusion:</b> 5-FU loaded NPs is promising nano-therapy against colon cancer.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}